FREDERICK, Md. ( DC News Now) — For the first time in 30 years, there is a new FDA-approved treatment for locally advanced pancreatic cancer. Frederick Health is the first in the U.S. to bring this ...

A new blood test detected early-stage pancreatic cancer with 87.5% accuracy in a study of 672 people. A new blood test that ...

The trial enrolled patients who received a triplet chemotherapy regimen of nab-paclitaxel, cisplatin, and gemcitabine.

A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

Pancreatic cancer is one of the hardest cancers to treat, which makes early detection so crucial, now AI is lending a hand to ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

Pioneering clinical trial testing how personalised mRNA vaccines can enable the immune system to target recurring pancreatic cancer.

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

Jean Trebek, Lisa Swayze, Joan Vassos, Stephen Nichols, Jeff Mauro, Jonathan Frakes, Kitty Swink, Rosa Blasi and Many More Raise [...] READ MORE ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...